This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
What: Chimerix (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, will visit the NASDAQ MarketSite in Times Square on Thursday, April 11, 2013. The Chimerix team, led by CEO
Kenneth I. Moch, will ring the Opening Bell in celebration of its initial public offering (IPO), which will occur on The NASDAQ Stock Market.
Where: NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
When: Thursday, April 11, 2013 – 9:15 a.m. to 9:30 a.m. ET
Contact: Kenneth I. Moch (919) 806-1074
firstname.lastname@example.orgNASDAQ MarketSite: Jen Knapp (212) 401-8916
Jennifer.email@example.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
Webcast: A live webcast of the NASDAQ Opening Bell will be available at:
Photos: To obtain a hi-resolution photograph of the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Chimerix (CMRX): Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens.
Chimerix's lead product candidate, CMX001, is a broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients. Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for AdV disease, an often-fatal infection which has no approved therapies. Since 2009, Chimerix has made CMX001 available under expanded access regulations to over 80 transplant centers worldwide for the treatment of over 430 patients with life-threatening dsDNA viral infections. Chimerix anticipates initiating SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adults undergoing HSCT, in 2013.